China’s National Medical Products Administration issued final implementation measures for drug trial data protection, positioning the country closer to global norms for pharmaceutical IP. The finalized rules mark a significant policy step for companies concerned about how clinical data are reused or challenged when seeking market access. The update is expected to affect filing strategies, partnership negotiations, and the timing of submissions across multi-country development plans. For biopharma, data exclusivity and protections remain central to the economics of novel therapy development, particularly for sponsors operating in multiple regulatory jurisdictions. The release also signals continued alignment with international expectations for clinical data stewardship and strengthens incentives for investment in China-origin innovations.